Effectiveness of devil's claw for osteoarthritis

S. Chrubasik, S. Pollak and A. Black1

Institut für Rechtsmedizin, Albertstrasse 9, University of Freiburg, 79104 Freiburg, Germany and
1 Department of Anaesthesia, University of Bristol, Bristol Royal Infirmary, Bristol BS2 8HW, UK

SIR, The recently published systematic review on complementary therapies for osteoarthritis [1] dealt primarily with arthritis of the hip and knee. Although some studies with mixed arthritic patterns were included, studies restricted to low back pain were specifically excluded. Two randomized placebo-controlled trials were cited concerning the effeciveness of Harpagophytum procumbens. Both investigated the effect of pulverized plant material containing 1.5 and 3% iridoid glycosides, and were no more than exploratory; one had no statistical calculation and the other no hypothesis. A recent definitive study [2] was not considered. It was designed with 90% power to detect a small difference [10 mm on a 100-mm visual analogue score (VAS) scale, with a background standard deviation of ~22 mm] between freeze-dried Harpagophytum and the weak non-steroidal anti-inflammatory drug (NSAID) diacerrhein for hip or knee pain. After 4 months, no statistically significant difference was found between the two treatments. The study showed that freeze-dried root tubers of Harpagophytum at a dose containing 60 mg harpagoside per day was as effective as, and had fewer side-effects than, diacerrhein. Table 1Go summarizes the types of controlled clinical studies with various Harpagophytum preparations that have been published in peer-reviewed journals [27]. The results of these studies demonstrate that Harpagophytum extracts with >50 mg harpagoside per day are helpful in alleviating pain. According to the ESCOP monograph [8], up to 9 g of crude drug with not less than 1% harpagoside is recommended for painful arthrosis and tendinitis—a dose that contains up to 90 mg of harpagoside. This marker is unlikely to be the only or even the most important active principle of the drug, but may contribute to its overall clinical effect. Although the higher concentrations of harpagoside that are found in volunteers' blood soon after ingestion of a dose of extract are associated with more in vitro inhibition of lipoxygenase than the lower concentrations in later samples [9], no such association has yet been demonstrated for therapeutic effect (e.g. pain relief, decrease in joint swelling). Stimulated release of inflammatory mediators (prostaglandin E2, cytokines) from human monocytes is not affected by harpagoside [10] and is a more appropriate test procedure for inflammation than treatment of whole blood with a compound that increases the calcium permeability of any cell [9]. More research is needed to investigate the contribution of the iridoid glycosides to the total effect.


View this table:
[in this window]
[in a new window]
 
TABLE 1. Clinical studies with medicinal products from devil's claw

 
A recent exploratory study of a proprietary ethanol extract of Harpagophytum providing only 24 mg harpagoside per day (Table 1Go) claimed significantly better effects than placebo. On the one hand one has to note that the group who received the extract had more initial pain than the placebo group and, as we have shown in multivariable modelling, greater initial pain tends to be associated with greater improvement [11, 12]. On the other hand it is likely that the ethanol extraction selects a range of less polar but more effective substances than does aqueous extraction, so it is possible that these putative substances are present in a greater proportion to harpagoside in ethanol extracts than in aqueous extracts. More work clearly needs to be done on what the active principle (sum of active ingredients) might be. More generally, the obvious heterogeneity in the range of Harpagophytum products means that no generic proof of their effectiveness is possible; the effectiveness has to be tested product by product.

Notes

Correspondence to: S. Chrubasik, Institut für Rechtsmedizin, University of Freiburg, Albertstrasse 9, 79104 Freiburg, Germany. Back

References

  1. Long L, Soeken K, Ernst E. Herbal medicines for the treatment of osteoarthritis: a systematic review. Rheumatology2001;40:770–93.
  2. Chantre P, Cappelaere A, Leblan D, Guedon D, Vandermander J, Fournie B. Efficacy and tolerability of Harpagophytum procumbens versus diacerhein in treatment of osteoarthritis. Phytomedicine2000;7:177–83.[ISI][Medline]
  3. Chrubasik S, Junck H, Breitschwerdt H, Conradt C, Zappe H. Effectiveness of Harpagophytum extract WS 1531 in the treatment of exacerbation of low back pain: a randomized placebo-controlled double-blind study. Eur J Anaesthesiol1999;16:118–29.[ISI][Medline]
  4. Chrubasik S, Zimpfer Ch, Schütt U, Ziegler R. Effectiveness of Harpagophytum procumbens in treatement of acute low back pain. Phytomedicine1996;3:1–10.[ISI]
  5. Chrubasik S, Model A, Black A, Pollak S. A randomized double-blind pilot study comparing Doloteffin and Vioxx in the treatment of low back pain. Rheumatology2002;41:in press.
  6. Chrubasik S, Schmidt A, Junck H, Pfisterer M. Wirksamkeit und Wirtschaftlichkeit von Teufelskrallenwurzelextrakt bei Rückenschmerzen: Erste Ergebnisse einer Anwendungsbeobachtung. Forsch Komplementärmed1997;4:332–6.
  7. Göbel H, Heinze A, Ingwersen M, Niederberger U, Gerber D. Harpagophytum-extrakt LI174 (Teufelskralle) bei der Behandlung unspezifischer Rückenschmerzen. Schmerz2001;19:10–9.
  8. ESCOP Monograph. Harpagophyti radix, Fascicule 2. Exeter, UK: ESCOP (European Scientific Cooperative on Phytotherapy), 1996.
  9. Loew D, Möllerfeld J, Schrödter A, Puttkammer S, Kaszin M. Investigations on the pharmacokinetic properties of Harpagophytum extracts and their effects on eicosanoid biosynthesis in vitro and in vivo. Clin Pharmacol Ther2001;69:356–64.[ISI][Medline]
  10. Chrubasik S, Fiebich B, Black A, Pollak S. Treating low back pain with an extract of Harpagophytum that inhibits cytokine release. Eur J Anaesthesiol Suppl2002;19:209.
  11. Chrubasik S, Künzel O, Acker A, Conradt C, Kerschbaumer V. Preliminary data on the effectiveness, safety and treatment cost of a willow bark special extract in outpatient treatment of low back pain: an open controlled study. Phytomedicine2001;8:241–51.[ISI][Medline]
  12. Chrubasik S, Künzel O, Model A, Conradt C, Black A. Treatment of low back pain with a herbal or synthetic antirheumatic: a randomized controlled study. Rheumatology2001;40:1388–93.[Abstract/Free Full Text]
Accepted 13 May 2002





This Article
Full Text (PDF)
Alert me when this article is cited
Alert me if a correction is posted
Services
Email this article to a friend
Similar articles in this journal
Similar articles in ISI Web of Science
Similar articles in PubMed
Alert me to new issues of the journal
Add to My Personal Archive
Download to citation manager
Disclaimer
Request Permissions
Google Scholar
Articles by Chrubasik, S.
Articles by Black, A.
PubMed
PubMed Citation
Articles by Chrubasik, S.
Articles by Black, A.
Related Collections
Osteoarthritis and Cartilage